TAK 003

Drug Profile

TAK 003

Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda Pharmaceuticals; Dengue vaccine tetravalent - Takeda Pharmaceuticals; DENVax™ - Takeda Pharmaceuticals; Needle-free dengue vaccine; TAK003; TDV - Takeda Pharmaceuticals; Tetravalent dengue vaccine - Takeda Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue

Most Recent Events

  • 20 Nov 2017 Takeda plans a phase III trial for Dengue (Prevention, In adolescents) in Mexico (SC) in November 2017 (NCT03341637)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Dengue(New delivery system, Prevention) in USA (Intradermal, Needle-free injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Dengue(Prevention) in Colombia (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top